(BBWI) Bath & Body Works - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0708301041
Stock: Body Care, Home Fragrance, Soaps, Sanitizers
Total Rating 50
Risk 68
Buy Signal -0.15
| Risk 5d forecast | |
|---|---|
| Volatility | 53.0% |
| Relative Tail Risk | -8.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.40 |
| Alpha | -60.98 |
| Character TTM | |
|---|---|
| Beta | 1.702 |
| Beta Downside | 2.027 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.98% |
| CAGR/Max DD | -0.22 |
EPS (Earnings per Share)
Revenue
Description: BBWI Bath & Body Works March 04, 2026
Bath & Body Works, Inc. (BBWI) is a specialty retailer. It sells home fragrance, personal care, and soap products.
The companys product lines include candles, diffusers, fine fragrance mists, and body care items. These are sold under brands like Bath & Body Works and White Barn.
BBWI operates through retail stores and e-commerce in the US and Canada. It also uses international franchise, license, and wholesale partnerships. This multi-channel approach is common in the retail sector for market penetration.
The company, founded in 1963, was formerly L Brands, Inc. before its name change in August 2021. Specialty retailers often focus on a narrow product category, allowing for deep product assortments and targeted marketing.
For more detailed financial analysis and competitive insights, consider exploring ValueRays platform.
Headlines to watch out for
- Consumer discretionary spending impacts fragrance and body care sales
- Supply chain disruptions increase product costs
- E-commerce growth expands market reach and revenue
- International expansion drives new revenue streams
- Input costs for fragrances and packaging affect margins
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 649.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 3.52 > 1.0 |
| NWC/Revenue: 5.87% < 20% (prev 8.10%; Δ -2.23% < -1%) |
| CFO/TA 0.22 > 3% & CFO 1.10b > Net Income 649.0m |
| Net Debt (4.00b) to EBITDA (1.40b): 2.85 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (211.6m) vs 12m ago -2.48% < -2% |
| Gross Margin: 43.73% > 18% (prev 0.44%; Δ 4.33k% > 0.5%) |
| Asset Turnover: 146.7% > 50% (prev 150.0%; Δ -3.29% > 0%) |
| Interest Coverage Ratio: 4.17 > 6 (EBITDA TTM 1.40b / Interest Expense TTM 276.0m) |
Altman Z'' 0.98
| A: 0.08 (Total Current Assets 2.02b - Total Current Liabilities 1.59b) / Total Assets 5.07b |
| B: -0.28 (Retained Earnings -1.44b / Total Assets 5.07b) |
| C: 0.23 (EBIT TTM 1.15b / Avg Total Assets 4.97b) |
| D: -0.20 (Book Value of Equity -1.25b / Total Liabilities 6.35b) |
| Altman-Z'' Score: 0.98 = BB |
Beneish M -3.23
| DSRI: 0.88 (Receivables 180.0m/205.0m, Revenue 7.29b/7.31b) |
| GMI: 1.01 (GM 43.73% / 44.25%) |
| AQI: 0.97 (AQ_t 0.19 / AQ_t-1 0.20) |
| SGI: 1.00 (Revenue 7.29b / 7.31b) |
| TATA: -0.09 (NI 649.0m - CFO 1.10b) / TA 5.07b) |
| Beneish M-Score: -3.23 (Cap -4..+1) = AA |
What is the price of BBWI shares?
As of March 19, 2026, the stock is trading at USD 20.27 with a total of 4,263,352 shares traded.
Over the past week, the price has changed by -0.35%, over one month by -15.74%, over three months by +2.69% and over the past year by -30.95%.
Over the past week, the price has changed by -0.35%, over one month by -15.74%, over three months by +2.69% and over the past year by -30.95%.
Is BBWI a buy, sell or hold?
Bath & Body Works has received a consensus analysts rating of 3.85.
Therefore, it is recommended to buy BBWI.
- StrongBuy: 7
- Buy: 4
- Hold: 8
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BBWI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.6 | 36.3% |
| Analysts Target Price | 27.6 | 36.3% |
BBWI Fundamental Data Overview March 15, 2026
P/E Trailing = 6.2701
P/E Forward = 6.2893
P/S = 0.5515
P/B = 1403.3759
P/EG = 0.723
Revenue TTM = 7.29b USD
EBIT TTM = 1.15b USD
EBITDA TTM = 1.40b USD
Long Term Debt = 3.89b USD (from longTermDebt, two quarters ago)
Short Term Debt = 475.0m USD (from shortTermDebt, last quarter)
Debt = 4.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.00b USD (from netDebt column, last quarter)
Enterprise Value = 8.02b USD (4.02b + Debt 4.95b - CCE 953.0m)
Interest Coverage Ratio = 4.17 (Ebit TTM 1.15b / Interest Expense TTM 276.0m)
EV/FCF = 9.27x (Enterprise Value 8.02b / FCF TTM 865.0m)
FCF Yield = 10.78% (FCF TTM 865.0m / Enterprise Value 8.02b)
FCF Margin = 11.86% (FCF TTM 865.0m / Revenue TTM 7.29b)
Net Margin = 8.90% (Net Income TTM 649.0m / Revenue TTM 7.29b)
Gross Margin = 43.73% ((Revenue TTM 7.29b - Cost of Revenue TTM 4.10b) / Revenue TTM)
Gross Margin QoQ = 45.67% (prev 41.28%)
Tobins Q-Ratio = 1.58 (Enterprise Value 8.02b / Total Assets 5.07b)
Interest Expense / Debt = 1.39% (Interest Expense 69.0m / Debt 4.95b)
Taxrate = 25.09% (135.0m / 538.0m)
NOPAT = 861.4m (EBIT 1.15b * (1 - 25.09%))
Current Ratio = 1.27 (Total Current Assets 2.02b / Total Current Liabilities 1.59b)
Debt / Equity = -3.87 (negative equity) (Debt 4.95b / totalStockholderEquity, last quarter -1.28b)
Debt / EBITDA = 2.85 (Net Debt 4.00b / EBITDA 1.40b)
Debt / FCF = 4.63 (Net Debt 4.00b / FCF TTM 865.0m)
Total Stockholder Equity = -1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.06% (Net Income 649.0m / Total Assets 5.07b)
RoE = -44.22% (negative equity) (Net Income TTM 649.0m / Total Stockholder Equity -1.47b)
RoCE = 47.47% (EBIT 1.15b / Capital Employed (Equity -1.47b + L.T.Debt 3.89b))
RoIC = 36.54% (NOPAT 861.4m / Invested Capital 2.36b)
WACC = 6.04% (E(4.02b)/V(8.97b) * Re(12.19%) + D(4.95b)/V(8.97b) * Rd(1.39%) * (1-Tc(0.25)))
Discount Rate = 12.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.47%
[DCF] Terminal Value 85.57% ; FCFF base≈783.0m ; Y1≈768.2m ; Y5≈782.9m
[DCF] Fair Price = 89.81 (EV 22.39b - Net Debt 4.00b = Equity 18.39b / Shares 204.7m; r=6.04% [WACC]; 5y FCF grow -2.82% → 2.90% )
EPS Correlation: 8.30 | EPS CAGR: 36.40% | SUE: 3.29 | # QB: 1
Revenue Correlation: 16.73 | Revenue CAGR: 18.31% | SUE: 3.18 | # QB: 1
EPS next Quarter (2026-04-30): EPS=0.29 | Chg7d=-0.001 | Chg30d=+0.007 | Revisions Net=-3 | Analysts=15
EPS current Year (2027-01-31): EPS=2.63 | Chg7d=-0.013 | Chg30d=+0.031 | Revisions Net=+5 | Growth EPS=-18.1% | Growth Revenue=-2.9%
EPS next Year (2028-01-31): EPS=2.87 | Chg7d=-0.002 | Chg30d=+0.080 | Revisions Net=+4 | Growth EPS=+9.0% | Growth Revenue=+2.2%
[Analyst] Revisions Ratio: -0.27 (4 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -3.8% (Discount Rate 12.2% - Earnings Yield 15.9%)
[Growth] Growth Spread = -0.7% (Analyst -4.5% - Implied -3.8%)
P/E Forward = 6.2893
P/S = 0.5515
P/B = 1403.3759
P/EG = 0.723
Revenue TTM = 7.29b USD
EBIT TTM = 1.15b USD
EBITDA TTM = 1.40b USD
Long Term Debt = 3.89b USD (from longTermDebt, two quarters ago)
Short Term Debt = 475.0m USD (from shortTermDebt, last quarter)
Debt = 4.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.00b USD (from netDebt column, last quarter)
Enterprise Value = 8.02b USD (4.02b + Debt 4.95b - CCE 953.0m)
Interest Coverage Ratio = 4.17 (Ebit TTM 1.15b / Interest Expense TTM 276.0m)
EV/FCF = 9.27x (Enterprise Value 8.02b / FCF TTM 865.0m)
FCF Yield = 10.78% (FCF TTM 865.0m / Enterprise Value 8.02b)
FCF Margin = 11.86% (FCF TTM 865.0m / Revenue TTM 7.29b)
Net Margin = 8.90% (Net Income TTM 649.0m / Revenue TTM 7.29b)
Gross Margin = 43.73% ((Revenue TTM 7.29b - Cost of Revenue TTM 4.10b) / Revenue TTM)
Gross Margin QoQ = 45.67% (prev 41.28%)
Tobins Q-Ratio = 1.58 (Enterprise Value 8.02b / Total Assets 5.07b)
Interest Expense / Debt = 1.39% (Interest Expense 69.0m / Debt 4.95b)
Taxrate = 25.09% (135.0m / 538.0m)
NOPAT = 861.4m (EBIT 1.15b * (1 - 25.09%))
Current Ratio = 1.27 (Total Current Assets 2.02b / Total Current Liabilities 1.59b)
Debt / Equity = -3.87 (negative equity) (Debt 4.95b / totalStockholderEquity, last quarter -1.28b)
Debt / EBITDA = 2.85 (Net Debt 4.00b / EBITDA 1.40b)
Debt / FCF = 4.63 (Net Debt 4.00b / FCF TTM 865.0m)
Total Stockholder Equity = -1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.06% (Net Income 649.0m / Total Assets 5.07b)
RoE = -44.22% (negative equity) (Net Income TTM 649.0m / Total Stockholder Equity -1.47b)
RoCE = 47.47% (EBIT 1.15b / Capital Employed (Equity -1.47b + L.T.Debt 3.89b))
RoIC = 36.54% (NOPAT 861.4m / Invested Capital 2.36b)
WACC = 6.04% (E(4.02b)/V(8.97b) * Re(12.19%) + D(4.95b)/V(8.97b) * Rd(1.39%) * (1-Tc(0.25)))
Discount Rate = 12.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.47%
[DCF] Terminal Value 85.57% ; FCFF base≈783.0m ; Y1≈768.2m ; Y5≈782.9m
[DCF] Fair Price = 89.81 (EV 22.39b - Net Debt 4.00b = Equity 18.39b / Shares 204.7m; r=6.04% [WACC]; 5y FCF grow -2.82% → 2.90% )
EPS Correlation: 8.30 | EPS CAGR: 36.40% | SUE: 3.29 | # QB: 1
Revenue Correlation: 16.73 | Revenue CAGR: 18.31% | SUE: 3.18 | # QB: 1
EPS next Quarter (2026-04-30): EPS=0.29 | Chg7d=-0.001 | Chg30d=+0.007 | Revisions Net=-3 | Analysts=15
EPS current Year (2027-01-31): EPS=2.63 | Chg7d=-0.013 | Chg30d=+0.031 | Revisions Net=+5 | Growth EPS=-18.1% | Growth Revenue=-2.9%
EPS next Year (2028-01-31): EPS=2.87 | Chg7d=-0.002 | Chg30d=+0.080 | Revisions Net=+4 | Growth EPS=+9.0% | Growth Revenue=+2.2%
[Analyst] Revisions Ratio: -0.27 (4 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -3.8% (Discount Rate 12.2% - Earnings Yield 15.9%)
[Growth] Growth Spread = -0.7% (Analyst -4.5% - Implied -3.8%)